342 related articles for article (PubMed ID: 26528286)
21. The emerging role of myeloid-derived suppressor cells in radiotherapy.
Kang C; Jeong SY; Song SY; Choi EK
Radiat Oncol J; 2020 Mar; 38(1):1-10. PubMed ID: 32229803
[TBL] [Abstract][Full Text] [Related]
22. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
23. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
[TBL] [Abstract][Full Text] [Related]
24. Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer.
Ko HJ; Kim YJ
Arch Pharm Res; 2016 Nov; 39(11):1597-1608. PubMed ID: 27572156
[TBL] [Abstract][Full Text] [Related]
25. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion.
Lu J; Luo Y; Rao D; Wang T; Lei Z; Chen X; Zhang B; Li Y; Liu B; Xia L; Huang W
Exp Hematol Oncol; 2024 Apr; 13(1):39. PubMed ID: 38609997
[TBL] [Abstract][Full Text] [Related]
26. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets.
Bizymi N; Bjelica S; Kittang AO; Mojsilovic S; Velegraki M; Pontikoglou C; Roussel M; Ersvær E; Santibañez JF; Lipoldová M; Papadaki HA
Hemasphere; 2019 Feb; 3(1):e168. PubMed ID: 31723807
[TBL] [Abstract][Full Text] [Related]
27. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer.
He ZN; Zhang CY; Zhao YW; He SL; Li Y; Shi BL; Hu JQ; Qi RZ; Hua BJ
Discov Oncol; 2023 Oct; 14(1):185. PubMed ID: 37857728
[TBL] [Abstract][Full Text] [Related]
28. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
[TBL] [Abstract][Full Text] [Related]
29. A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response.
Chakraborty P; Das S; Banerjee K; Sinha A; Roy S; Chatterjee M; Choudhuri SK
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):165-75. PubMed ID: 24611750
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
Di Mitri D; Toso A; Alimonti A
Clin Cancer Res; 2015 Jul; 21(14):3108-12. PubMed ID: 25967145
[TBL] [Abstract][Full Text] [Related]
31. Drafting the proteome landscape of myeloid-derived suppressor cells.
Gato M; Blanco-Luquin I; Zudaire M; de Morentin XM; Perez-Valderrama E; Zabaleta A; Kochan G; Escors D; Fernandez-Irigoyen J; Santamaría E
Proteomics; 2016 Jan; 16(2):367-78. PubMed ID: 26403437
[TBL] [Abstract][Full Text] [Related]
32. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.
Katoh H; Watanabe M
Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490
[TBL] [Abstract][Full Text] [Related]
33. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
Ye XZ; Yu SC; Bian XW
J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
[TBL] [Abstract][Full Text] [Related]
34. Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment.
Li Y; He H; Jihu R; Zhou J; Zeng R; Yan H
Front Cell Dev Biol; 2021; 9():698532. PubMed ID: 34527668
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
36. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
37. Amino acid metabolism related to immune tolerance by MDSCs.
Yang B; Wang X; Ren X
Int Rev Immunol; 2012 Jun; 31(3):177-83. PubMed ID: 22587019
[TBL] [Abstract][Full Text] [Related]
38. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.
Lee JM; Seo JH; Kim YJ; Kim YS; Ko HJ; Kang CY
Int J Cancer; 2012 Aug; 131(3):741-51. PubMed ID: 21898392
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.
Sade-Feldman M; Kanterman J; Ish-Shalom E; Elnekave M; Horwitz E; Baniyash M
Immunity; 2013 Mar; 38(3):541-54. PubMed ID: 23477736
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
